- Home
- HIHO vs KZIA Comparison
HIHO vs KZIA Comparison
Compare HIHO & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HIHO
- KZIA
- Stock Information
- Founded
- HIHO 1990
- KZIA 1994
- Country
- HIHO Hong Kong
- KZIA Australia
- Employees
- HIHO N/A
- KZIA N/A
- Industry
- HIHO Industrial Machinery/Components
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- HIHO Industrials
- KZIA Health Care
- Exchange
- HIHO Nasdaq
- KZIA Nasdaq
- Market Cap
- HIHO 8.2M
- KZIA 6.0M
- IPO Year
- HIHO 1996
- KZIA 1999
- Fundamental
- Price
- HIHO $1.88
- KZIA $0.89
- Analyst Decision
- HIHO
- KZIA Strong Buy
- Analyst Count
- HIHO 0
- KZIA 2
- Target Price
- HIHO N/A
- KZIA $11.50
- AVG Volume (30 Days)
- HIHO 4.0K
- KZIA 5.5M
- Earning Date
- HIHO 01-21-2025
- KZIA 03-26-2025
- Dividend Yield
- HIHO 6.42%
- KZIA N/A
- EPS Growth
- HIHO N/A
- KZIA N/A
- EPS
- HIHO N/A
- KZIA N/A
- Revenue
- HIHO $7,345,000.00
- KZIA $1,655,324.00
- Revenue This Year
- HIHO N/A
- KZIA $806.89
- Revenue Next Year
- HIHO N/A
- KZIA N/A
- P/E Ratio
- HIHO N/A
- KZIA N/A
- Revenue Growth
- HIHO 11.36
- KZIA 248000.00
- 52 Week Low
- HIHO $1.70
- KZIA $0.89
- 52 Week High
- HIHO $2.88
- KZIA $15.80
- Technical
- Relative Strength Index (RSI)
- HIHO 48.27
- KZIA 28.96
- Support Level
- HIHO $1.83
- KZIA $0.90
- Resistance Level
- HIHO $1.94
- KZIA $1.60
- Average True Range (ATR)
- HIHO 0.04
- KZIA 0.24
- MACD
- HIHO 0.00
- KZIA 0.01
- Stochastic Oscillator
- HIHO 42.27
- KZIA 0.00
About HIHO Highway Holdings Limited
Highway Holdings Ltd is a holding company. The company is a manufacturer of metal, plastic, electric and electronic components for original equipment manufacturers (OEM) and contract manufacturers. Its operating segment includes Metal stamping and mechanical OEM and Electric OEM. The metal stamping segment focuses on the manufacturing and sale of metal parts and components. The company generates maximum revenue from the Metal stamping and mechanical OEM segment. Geographically, it derives a majority of its revenue from Europe and also has a presence in Hong Kong and China, North America, and Other Asian countries.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.